<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949741</url>
  </required_header>
  <id_info>
    <org_study_id>CFM</org_study_id>
    <nct_id>NCT00949741</nct_id>
  </id_info>
  <brief_title>Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients</brief_title>
  <acronym>CFM</acronym>
  <official_title>Observational Retrospective Multicenter Study for the Citofluorimetric Analysis of Cerebrospinal Fluid Vs Conventional Method in Patients With Aggressive Non-Hodgkin's Lymphoma Without Leptomeningeal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to define if flow cytometry has more sensitivity for detecting
      neoplastic cells in cerebrospinal fluid versus conventional cytology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aggressive B-cell non-Hodgkin's lymphoma (B-NHL), Lymphoblastic Lymphoma and Burkitt's
      Lymphoma are at high risk of CNS relapse. For this reason is recommended a prophylaxis
      therapy. This suggests that negative leptomeningeal localization patients at diagnosis are
      really positive and that would be a very high risk of CNS relapse subtype patients. It's very
      important detecting neoplastic cells in cerebrospinal fluid as soon as possible. This study
      will evaluate only patients that have been flow cytometry and cytology at diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of diagnostic agreement of citofluorimentria flow in the research of lymphoma cells in the cerebrospinal fluid vs cell morphology.</measure>
    <time_frame>Evaluation at diagnosis</time_frame>
    <description>Evaluation of diagnostic agreement of citofluorimentria flow in the research of lymphoma cells in the cerebrospinal fluid vs cell morphology. The second test will be performed independently and without the cytologist is aware of the outcome of the analysis by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of all paper forms</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">175</enrollment>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Burkitt's Lymphoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by aggressive non-Hodgkin's lymphoma at diagnosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of

               -  Diffuse large cell lymphoma HIV positive,

               -  Lymphoblastic lymphoma,

               -  Burkitt's lymphoma,

               -  Mantle cell lymphoma blastoid type.

          2. DLCL patients who presented one risk factor for leptomeningeal involvement as:

               -  testis, bone marrow, orbit, palate, paranasal cavity or peridural disease
                  localization,

               -  2-3 age-adjusted IPI score with more than 1 extranodal site and LDH &gt; normal.

          3. Patients with cytologic and flow cytometry on cerebrospinal fluid at diagnosis.

        Exclusion Criteria:

        1. Patients with clinical or strumental evidence of meningeal localization disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Vitolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCDO Ematologia AOU San Giovanni Battista Torino Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASO SS Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO Centro Binaghi Divisione di Ematologia CTMO</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi Divisione di Ematologia</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardinale Panico</name>
      <address>
        <city>Tricase</city>
        <state>LE</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di riferimento Oncologico Divisione Oncologia A</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Univ. Policlinico Tor Vergata Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università La Sapienza Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Università del Piemonte Orientalr</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDO Ematologia 2 AOU San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>October 21, 2013</last_update_submitted>
  <last_update_submitted_qc>October 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

